Enforcing CSR among food manufacturers in Malaysia through legal and institutional framework

Corporate Social Responsibility (CSR) is a concept in which corporations take into account the interest of the society in four areas of responsibility namely economic, legal, ethical, and philanthropic. In the area of food manufacturing, corporate social responsibility plays a vital role by ensuring that food is healthy and in adherence to safety standards. The Food Act 1983 and Food Regulations 1985 play an important role in enforcing corporate social responsibility amongst food manufacturers. Institutional framework in Malaysia such as, Ministry of Health, Food and Safety Quality Division and FOSIM were established to ensure that food-processing activities are according to the required hygiene and safety standards.It is discovered through National Consumer Complaint Centre reports that the enforcement in food safety needs improvement. The paper also examines the role of non-governmental agencies, namely, the Consumer Association of Penang and the National Consumer Complaints Centre, in channeling and documenting complaints from consumers to relevant enforcement agencies. This paper intends to analyse the duties of food manufacturers and to identify legislations that enforce CSR amongst food manufacturers. Adopting the content analysis method, this paper will examine the principle of CSR as contained in the Food Act 1983. This paper further discusses the roles of institutional frameworks namely, the Ministry of Health, Food Safety and Quality Division and FOSIM in enforcing corporate social responsibility amongst food manufacturers.This article aims to contribute namely to various stakeholders ie: the government in which CSR policies can be connected to food safety through our hard and soft laws and consumers will be more aware and educated in which they will support food companies that are implementing CSR in their food production. The paper also serves as a guide to food manufacturers as they will be more particular in their CSR efforts to garner more support towards their food products. With a good CSR policy and food safety efforts Malaysia will be able to increase its revenue in import and export of food products

A Case Study on Ranhill Water Services and Syarikat Air Negeri Sembilan in Combating the Non-Revenue Water Problem in Johor and Negeri Sembilan

Up to date, Non-Revenue Water (NRW) is still a problem in many states. This study is focused on the states of Negeri Sembilan and Johor. A team of Malaysian lecturers from Faculty of Accountancy and Management, Universiti Tunku Abdul Rahman (UTAR), under the Malaysian governmental grant (TRGS 2016-1) are researching how to combat the NRW problem in the states of Negeri Sembilan and Johor. Data were collected through field research and focus group interviews from both Ranhill Water Services Sdn Bhd (Ranhill) and Syarikat Air Negeri Sembilan Sdn Bhd (SAINS). This study also looked into the laws and several legal cases involving non-revenue in Malaysia. Our research questions are what is non-revenue water, what are the institutions governing non-revenue water in Malaysia, what are the legislations and cases of non-revenue water in Malaysia and how do we overcome non-revenue water in Malaysia based on findings from Johor and Negeri Sembilan. From the research have found that the main contributors to NRW in Johor are a leakage in their pipe system and also reservoir overflow. They are now utilizing loggers to detect leakage. It was highlighted that amongst the challenges to combat NRW are the acknowledgement and awareness on the client-side and educating the client on the true situation of the pipe conditions and how to manage the NRW problem. As for SAINS, awareness is the same issue faced by SAINS just like Ranhill in which 80.0% are still more focused towards water supply rather than NRW

How much does HIV self-testing cost in low and middle income countries? A systematic review of evidence from economic studies

ObjectivesHIV self-testing (HIVST) has been proposed as an innovative strategy to diagnose human immunodeficiency virus (HIV). While HIVST offers the potential to broaden accessibility of early HIV diagnosis and treatment initiation, this testing strategy incurs additional cost and requires confirmatory testing and treatment. We have conducted the first systematic review to summarize the current economic literature for HIVST in low- and middle-income countries (LMICs).DesignA search strategy was developed including key terms for HIV, self-testing and cost-effectiveness and was conducted in Medline and Embase databases. Studies were included that reported costs per outcome and included both cost-effectiveness and cost-utility outcome measures. The search strategy identified publications up until August 15, 2023 were included. Abstract and full text screening was conducted and a standardized data abstraction form was used for included studies. Costs are reported in USD, 2020.ResultsOur search strategy identified 536 total titles from the search strategy, which were screened down to 25 relevant studies that provided both cost and outcome data on HIVST. There was significant heterogeneity in the HIVST intervention, study population, costs and outcomes reported among included studies. Cost per person tested ranged from $1.09–155. Cost per case diagnosed ranged from$20–1,277. Cost-utility estimates ranged from cost-saving to $1846 per DALY averted. Higher cost-effectiveness estimates were associated with more expensive testing algorithms with increased support for linkage to care and post-test counseling.ConclusionAll studies considered HIVST cost-effective although major drivers were identified included underlying HIV prevalence, testing cost and linkage to care. HIVST is likely to be cost-effective in a LMIC context, however policy makers should be aware of the drivers of cost-effectiveness when implementing HIVST programs as these underlying factors can impact the overall cost-effectiveness of HIVST

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

Funder: laura and john arnold foundationBACKGROUND: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). METHODS: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. RESULTS: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. CONCLUSIONS: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Des ressources naturelles à la santé: Approche interdisciplinaire de la production des goudrons de conifères et de leur usage médicinal en Méditerranée sur la longue durée

National audienc

Additional file 2 of Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Additional file 2. Email invitation

Additional file 7 of Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Additional file 7. Sensitivity analyses: various meta-analytic approaches

Additional file 1 of Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Additional file 1. Search strategy